# Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

> **NCT06254560** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (estimated)

## Conditions studied

- Severe Aplastic Anemia
- Platelet Transfusion Refractoriness

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06254560
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-23
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06254560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06254560, "Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT06254560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*